| Literature DB >> 24222911 |
Zefeng Wang1, Haitong Wan, Jinhui Li, Hong Zhang, Mei Tian.
Abstract
With the speeding tendency of aging society, human neurological disorders have posed an ever increasing threat to public health care. Human neurological diseases include ischemic brain injury, Alzheimer's disease, Parkinson's disease, and spinal cord injury, which are induced by impairment or specific degeneration of different types of neurons in central nervous system. Currently, there are no more effective treatments against these diseases. Traditional Chinese medicine (TCM) is focused on, which can provide new strategies for the therapy in neurological disorders. TCM, including Chinese herb medicine, acupuncture, and other nonmedication therapies, has its unique therapies in treating neurological diseases. In order to improve the treatment of these disorders by optimizing strategies using TCM and evaluate the therapeutic effects, we have summarized molecular imaging, a new promising technology, to assess noninvasively disease specific in cellular and molecular levels of living models in vivo, that was applied in TCM therapy for neurological diseases. In this review, we mainly focus on applying diverse molecular imaging methodologies in different TCM therapies and monitoring neurological disease, and unveiling the mysteries of TCM.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24222911 PMCID: PMC3814075 DOI: 10.1155/2013/608430
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Traditional Chinese medicine therapy in neurological disease models of animal or human.
| TCM type | Drug or acupoints | Disease models | Therapy time (days) | Functional outcome | References |
|---|---|---|---|---|---|
| CHM | BHD | MCAO (rats) | 14 | Enhanced neurological recovery | [ |
| CI/R (mice) | 14 | Improved functional recovery | [ | ||
| CIG | AD (rats) | 28 | Promoted neuronal survival and brain repair | [ | |
| Triptolide | PD (rats) | 24 | And inflammatory reactivity | [ | |
|
| |||||
| ACU | ST36, SP6 | PD (mice) | 13 | Protected the nigrostriatal system | [ |
| CV6, 12, 17, | AD (mice) | 15 | Improved cognitive deficits, reduced neurons loss | [ | |
|
| |||||
| CUP | BL, GV | PD (human) | 30 | Attenuated neurological symptoms | [ |
CHM: Chinese herb medicine; ACU: acupuncture; CUP: cupping; BHD: Bu-yang Huan-wu decoction; CIG: cornel iridoid glycoside; ST36: Zusanli; SP6: Sanyinjiao; CV6: Qihai; CV12: Zhongwan; CV17: Tanzhong; SP10: bilateral Xuehai; BL: Bladder meridian or channel of foot greater Yang; GV: governor vessel; MCAO: middle cerebral artery occlusion; CI/R: middle cerebral ischemic/reperfusion; AD: Alzheimer's disease; PD: Parkinson's disease.
Molecular imaging in traditional Chinese medicine therapy for neurological disease.
| Disease models | CHM type | Drug or acupoints | Tracers | Modality | Functional outcome | References |
|---|---|---|---|---|---|---|
| MCAO (rats) | CHM | ASG IV-TMPZ | 18F-FDG | PET | Enhanced functional recovery and glucose metabolism | [ |
| MCAO (rats) | CHM | CXQ-PUE | 18F-FDG | PET | Recovery glucose metabolism, | [ |
| MCAO (rats) | CHM | BAI-JAS | NULL | DWI-MRI | Enhanced cerebral ischemia injury repair | [ |
| MCAO (rats) | ACU | DU14, 20 | NULL | DTI-MRI | Improved neurons regeneration | [ |
| WD (human) | ACU | Du20, 23, EXH- | NULL | DTI-MRI | Improved functional recovery | [ |
| Stroke (human) | ACU | LI 14, LI11 | NULL | fMRI | Enhanced functional recovery | [ |
| Stroke (human) | CHM | CG | NULL | T2W-MRI | Ameliorated brain edema | [ |
| MCAO (rats) | ACU | GV20 | NULL | DWI-MRI | Alleviated brain oedema | [ |
| MCAO (rats) | ACU | GV20, GV26 | 18F-FDG | DWI-MRI and PET | Improved metabolic recovery, reduced the injuryvolume | [ |
| AD (mice) | CHM | Evodiamine | 18F-FDG | PET/CT | Improved glucose uptake and cognitive abilities | [ |
| AD (rats) | CHM | Fuzhisan | 18F-FDG | PET | Ameliorated glucose metabolism of brain | [ |
| AD (human) | CHM | Fuzhisan | 18F-FDG | PET | Increased rCMRglc | [ |
| AD (human) | ACU | ST36, 40, HT7, KI3 | NULL | fMRI | Improved cognitive function | [ |
| AD (human) | ACU | Liv3, LI4 | NULL | fMRI | Enhanced cognitive recovery | [ |
| PD (human) | ACU | MS4, 6, 9, 14 | 18F-FDG | PET | Improve cerebral glucose metabolism | [ |
| PD (human) | ACU | MS4, 6, 8, 9, 14 | 99mTc-E, 9mTc-T4 | SPECT | Increased rCBF | [ |
| PD (mice) | ACU | PC 7 | [123I]-IBZM | SPECT | Attenuated neuronal damage | [ |
MCAO: middle cerebral artery occlusion; WD: wallerian degeneration; AD: Alzheimer's disease; PD: Parkinson's disease; CHM: Chinese herb medicine; ACU: acupuncture; ASG IV: Astragaloside IV; TMPZ: tetramethylpyrazine; CXQ-PUE: chuanxiongzine and puerarin; BAI-JAS: baicalin and jasminoidin; DU20: Baihui; DU14: Dazhui; LI10: Shousanli; ST36: Zusanli; Du 23: Shangxin; EXHN3: Yintang; PC6: Neiguan; Sp6: Sanyingjiao; LI11: Quch; LI14: Binao; CG: cerebralcare granule; GV20: Baihu; GV26: Shuigou; HT7: Shenmen; ST36: Zusanii; ST40; Fenglong; KI3: Taixi; Liv3: Taichong; LI4: Hegu; MS6: the anterior oblique meridian of the vertex to temple; MS4: the lateral III meridian on forehead; MS8: the lateral I meridian of the vertex; MS9: the lateral II meridian of the vertex; MS14: lower-lateral meridian of the occiput; MS8: the lateral I meridian of the vertex; PC: Daling; [18F] FDG: 2-deoxy-2-(18F)fluoro-D-glucose; 99mTc-E 99mTc-ECD: technetium-99m ethyl cysteinate dimer; 99mTc-T4: 99mTc-TRODAT-4; [123I] IBZM: 123I-iodobenzamide; rCMRglc: regional cerebral metabolic rate of glucose consumption; rCBF: regional cerebral blood flow.
Figure 118F-FDG-PET images of activity of hibateral hippocampus regions glucose metabolism in rats to evaluate the effects both Astragaloside IV (ASG IV) and tetramethylpyrazine (TMPZ) on the cerebral ischemia-reperfusion injury. (a) Sham group, (b) model group, (c) ASG IV group, (d) ASG IV-TMPZ group, and (e) nimodipine group. The glucose metabolism of the ASG IV-TMPZ group was significantly recovered in the right area of cerebrum compared with other groups [31].
Figure 2fMRI images of regions showing increased or decreased activities in entire brain of Alzheimer's disease patients after acupuncture compared with the resting state. Left in picture is left in the brain. The color scale represents t values [60].
Figure 3[123I]IBZM-SPECT images of the acupuncture-treated MPTP-induced Parkinson's disease mice. The left is sham acupuncture (SA) group, and the right is retained acupuncture (RA) group. The intensity of radionuclide or radiopharmaceutical uptake in RA group is higher than that in SA group [65].